The Zhitong Finance App learned that Axsome Therapeutics (AXSM.US), a biopharmaceutical company focused on developing and commercializing novel treatments for central nervous system (CNS) diseases, announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority review to the marketing application submitted to expand the indications of its depression treatment AXS-05 (trade name: Auvelity) to the excitation symptoms of Alzheimer's disease. The company said in a statement that the FDA has set April 30, 2026 as the target review completion date for AXS-05's new drug supplement application. Boosted by this news, as of press release, Axsome's US stocks rose more than 7% before the market on Wednesday.

The Zhitong Finance App learned that Axsome Therapeutics (AXSM.US), a biopharmaceutical company focused on developing and commercializing novel treatments for central nervous system (CNS) diseases, announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority review to the marketing application submitted to expand the indications of its depression treatment AXS-05 (trade name: Auvelity) to the excitation symptoms of Alzheimer's disease. The company said in a statement that the FDA has set April 30, 2026 as the target review completion date for AXS-05's new drug supplement application. Boosted by this news, as of press release, Axsome's US stocks rose more than 7% before the market on Wednesday.